Skip to content

Supernus Pharmaceuticals SUPN Cash Flow Statement

Q1 '26Q4 '25Q3 '25Q2 '25Q1 '25
-$2.29M+44.1%-$4.11M+90.9%-$45.12M-301%$22.5M+290%-$11.83M-177%
$26.13M+4.5%$25.02M+0.8%$24.81M+16.1%$21.36M+4.8%$20.38M+8.2%
$8.48M-12.1%$9.65M+23.3%$7.83M+4.2%$7.51M-7.0%$8.07M+5.7%
$66.52M+235%$19.86M$58.54M+91.3%$30.6M-31.1%
$0-100%$427K+231%$129K-71.6%$455K+39.1%$327K+53.5%
-$19.22M$48.71M$37.32M+395%
$9.12M+6.9%$8.53M-59.5%$21.07M+2,153%$935K+104%-$21.4M-463%
$56.42M$8.11M-71.9%$28.86M-38.0%$46.52M
$66.52M+242%$19.43M$58.08M+91.9%$30.27M-31.5%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does Supernus Pharmaceuticals generate?
Supernus Pharmaceuticals (SUPN) generated $175.5M in operating cash flow over the trailing twelve months.
What is Supernus Pharmaceuticals's free cash flow?
After $1.0M of capital expenditures, Supernus Pharmaceuticals's free cash flow was $174.3M over the trailing twelve months, up 1.8% year over year.
Where does Supernus Pharmaceuticals's cash flow data come from?
Every line is extracted from Supernus Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.